Shenzhen Bioeasy Biotechnology Co., Ltd. — Investor Relations & Filings
Shenzhen Bioeasy Biotechnology Co., Ltd. specializes in the development, production, and marketing of rapid testing solutions for food safety, clinical diagnosis, and animal health. The company provides a comprehensive portfolio of diagnostic products, including rapid test strips, enzyme-linked immunosorbent assay (ELISA) kits, and automated detection instruments. Its core focus areas include the detection of antibiotic residues, mycotoxins, pesticides, and foodborne pathogens in dairy, meat, seafood, and grain products. In the clinical sector, Bioeasy offers point-of-care testing (POCT) solutions for infectious diseases and chronic conditions. The company emphasizes research and development to deliver high-sensitivity, user-friendly diagnostic tools that meet international quality standards. Its products are utilized by food producers, regulatory agencies, and healthcare providers to ensure safety and quality control across the global supply chain.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 关于实施2025年度权益分派期间“易瑞转债”暂停转股的公告 | 2026-05-21 | Chinese | |
| 2025年度股东会决议公告 | 2026-05-18 | Chinese | |
| 国浩律师（深圳）事务所关于深圳市易瑞生物技术股份有限公司2025年度股东会法律意见书 | 2026-05-18 | Chinese | |
| 2025年度独立董事述职报告（袁若宾) | 2026-04-26 | Chinese | |
| 2025年度内部控制自我评价报告 | 2026-04-26 | Chinese | |
| 关于变更公司高级管理人员的公告 | 2026-04-26 | Chinese |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46733778 | 关于实施2025年度权益分派期间“易瑞转债”暂停转股的公告 | 2026-05-21 | Chinese | ||
| 46384993 | 2025年度股东会决议公告 | 2026-05-18 | Chinese | ||
| 46384990 | 国浩律师（深圳）事务所关于深圳市易瑞生物技术股份有限公司2025年度股东会法律意见书 | 2026-05-18 | Chinese | ||
| 39196856 | 2025年度独立董事述职报告（袁若宾) | 2026-04-26 | Chinese | ||
| 39196852 | 2025年度内部控制自我评价报告 | 2026-04-26 | Chinese | ||
| 39196848 | 关于变更公司高级管理人员的公告 | 2026-04-26 | Chinese | ||
| 39196846 | 关于召开公司2025年度股东会的通知 | 2026-04-26 | Chinese | ||
| 39196842 | 华兴会计师事务所(特殊普通合伙)关于深圳市易瑞生物技术股份有限公司非经营性资金占用及其他关联资金往来情况的专项报告 | 2026-04-26 | Chinese | ||
| 39196839 | 2025年年度审计报告 | 2026-04-26 | Chinese | ||
| 39196836 | 2025年年度报告摘要 | 2026-04-26 | Chinese | ||
| 39196833 | 东兴证券股份有限公司关于深圳市易瑞生物技术股份有限公司2025年度现场检查报告 | 2026-04-26 | Chinese | ||
| 39196832 | 关于会计政策变更的公告 | 2026-04-26 | Chinese | ||
| 39196829 | 董事会审计委员会对会计师事务所2025年度履职情况评估及履行监督职责情况的报告 | 2026-04-26 | Chinese | ||
| 39196828 | 东兴证券股份有限公司关于深圳市易瑞生物技术股份有限公司2025年度持续督导跟踪报告 | 2026-04-26 | Chinese | ||
| 39196825 | 关于2025年度计提资产减值准备的公告 | 2026-04-26 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Shenzhen Bioeasy Biotechnology Co., Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/55906/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=55906 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=55906 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=55906 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 55906}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Shenzhen Bioeasy Biotechnology Co., Ltd. (id: 55906)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.